1. Executive view – what changed since our previous PLX reports

Our earlier PLX pieces laid out a relatively simple story: a small rare-disease platform with two commercial enzyme replacement therapies, a differentiated plant-cell manufacturing system and a gout program that could eventually become the main driver if it makes it through development. The positive CHMP opinion on Elfabrio’s 2 mg/kg every-4-weeks regimen was the first major “label-depth” step for the Fabry franchise rather than a new binary approval.

Since then, the picture has sharpened along three axes that converge in March 2026. First, the CHMP’s E4W opinion has moved from “regulatory ask” to “positive recommendation”, putting a potential 25 M USD milestone and a tangible quality-of-life upgrade for patients on the table once the European Commission signs off. Second, the financials confirmed that 2024 was Protalix’s first profitable year at the bottom line, with around 53 M USD of product revenues and roughly 2.9 M USD net income, while 9M 2025 results show continued growth but more volatility on working capital. Third, the share price has quietly travelled from the 1.3–1.5 USD area to just over 3 USD, now glued to a resistance band that lines up with last year’s highs.

The result is a very different starting point compared with the earlier PLX narrative: this is no longer a deep-value story stuck at the bottom of the range, but a name where March’s events will play out against a tape already discounting part of the good news. That does not make the story “better” or “worse” in absolute terms – it simply changes the risk/reward profile around the upcoming catalysts.

2. Business & financial check – Elfabrio, Elelyso and the balance sheet

2.1. Revenue mix and profitability

The 2024 Form 10-K confirms that Protalix generated roughly 53 M USD in revenues from selling goods, with the mix dominated by Elfabrio product sold to its Fabry partner and, to a lesser extent, Elelyso sales to Pfizer and supply into Brazil. Management reported net income of approximately 2.9 M USD for the year, turning the company profitable after years of losses driven by R&D and financing costs.

Nine-month 2025 figures show continued growth in revenues from selling goods into the low-40M USD range, up mid-20% versus the same period in 2024. However, the bottom line for 9M 2025 is modestly negative – a net loss of around 1.1 M USD – despite a profitable Q3, largely because of movements in accounts receivable and other working-capital items rather than an underlying deterioration in the business.

2.2. Cash, deposits and runway

Liquidity is always central in a small-cap biotech, particularly one that has just begun to generate consistent product-based profits. Across its filings, Protalix repeatedly emphasises that its mix of cash, cash equivalents and short-term bank deposits is sufficient to cover at least twelve months of capital needs from the date of the latest report. That statement matters more than the exact headline figure on a specific quarter-end, because it explicitly ties the runway assessment to management’s budgeting and collaboration expectations.

In practice, the 10-K and subsequent 10-Qs point to a liquidity profile in the low-30M USD area when aggregating cash and short-term deposits. On the liability side, the company has removed the convertible notes overhang, with the remaining debt load largely limited to leases and operating-type obligations. This combination – a modest but tangible cash cushion, a profitable or near-breakeven P&L and no meaningful financial debt – is what makes milestones and partner economics (such as the 25 M USD Elfabrio E4W payment) unusually impactful relative to the market cap.

2.3. What to watch in the upcoming full-year 2025 results

Third-party earnings calendars currently project a window around mid-March 2026 (roughly March 11–17) for the full-year 2025 results and call. This timing is an estimate derived from external data vendors, not from an official company announcement, and the actual release could still fall in late March or even early April. Until the press release is out, the date has to be treated as provisional. What is more stable is the expected sequence: headline revenue growth, an update on Elfabrio and Elelyso traction, confirmation on cash and deposits, and a qualitative update on PRX-115 and PRX-119 progress.

• Revenues from selling goods: whether 2025 lands comfortably ahead of 2024’s ≈53 M USD baseline, and how much of the growth comes from Elfabrio.
• Operating margin: any sign that 2024’s profitability can be sustained or improved, versus a scenario where higher R&D spend pushes the company back into the red.
• Cash and runway: fresh management language around the “12-month” runway statement, especially in the context of potential milestone timing.

3. March 2026 catalyst cluster – EU E4W decision, full-year call, pipeline signals

The next few weeks concentrate several moving parts for PLX. It is helpful to think in terms of a “cluster” rather than a single binary event: none of the individual items resembles a classic make-or-break PDUFA, but together they will refresh the market’s view on Elfabrio’s trajectory, the health of the balance sheet and the credibility of the gout program.

3.1. EU decision on Elfabrio 2 mg/kg every four weeks

The CHMP has already issued a positive opinion recommending approval of an additional regimen for Elfabrio: 2 mg/kg body weight every four weeks (E4W) for eligible adult Fabry patients who are stable on enzyme replacement therapy. The European Commission now has to convert that opinion into a formal decision on the label change. That process typically takes a few weeks, and a late-Q1 / early-Q2 2026 window is a reasonable working assumption, though the exact date is not fixed.

For trading purposes, what matters is less the formal timing and more the content:

• The E4W option is designed to reduce infusion frequency for appropriate patients, directly targeting treatment burden and adherence.
• If the Commission approves the new regimen, Protalix becomes eligible for a regulatory milestone payment of roughly 25 M USD from its partner. Against a market cap in the mid-hundreds of millions and a cash balance in the low-30M USD range, that is material.
• Strategically, the approval would deepen the Elfabrio franchise in Europe and refine its positioning versus other ERTs and oral Fabry options, without raising new efficacy or safety questions in the core label.

3.2. Full-year 2025 results and guidance tone

The full-year 2025 call will be the first one fully reflecting Elfabrio’s early ramp, the stabilisation of Elelyso flows and the initial spend required to move PRX-115 further along. Because of that, the qualitative message may matter as much as the absolute numbers. Investors will be listening for clues on:

• How management frames Elfabrio’s growth runway in Fabry: is E4W presented as a significant driver of patient switching and adherence over time, or more as an incremental convenience option?
• Capital allocation and dilution stance: whether the company hints at equity raises, leans harder on non-dilutive collaboration cash, or signals that the current cash/royalty mix can sustain the plan for another year.
• PRX-115 and PRX-119 milestones: any updated timelines for trial starts, dose-finding data or partnership-related payments.

3.3. Pipeline outlook – PRX-115 (uncontrolled gout) and PRX-119

The gout asset, PRX-115, remains a key medium-term lever. The basic thesis is unchanged: a sub-population of uncontrolled gout patients where existing urate-lowering therapies fail or are poorly tolerated, and where a biologic with compelling urate-lowering and tolerability data could find a clear niche. In the short term, what matters is whether Protalix can keep the asset advancing without over-stretching its balance sheet.

In 2025–2026, investors should watch for concrete development steps – final protocol designs, first-patient-in announcements, early safety and pharmacodynamic signals – rather than expecting large, de-risking readouts. Any partner-related milestone or opt-in decision would also be important, both for validating the program and for providing non-dilutive cash.

4. Technical view – a stock leaning on resistance into news

The technical set-up is straightforward but important: PLX has rallied from roughly 1.3–1.5 USD to just above 3 USD over the last twelve months, taking out intermediate resistance levels and establishing a pattern of higher highs and higher lows. The current zone around 3.0–3.2 USD coincides with the upper band of the 52-week range and with prior swing highs where the stock previously hesitated.

Into that backdrop, the moving averages tell a consistent story. On most standard timeframes, the price sits above both the 50-day and 200-day moving averages, with the shorter one trending above the longer one – a textbook sign of an established uptrend. Periodic pullbacks have tended to find support near the rising 50-day line or around prior breakout levels, suggesting that medium-term holders have been willing to defend the trend so far.

From a risk-management standpoint, that means the March catalysts will not be hitting a depressed, washed-out chart but one where expectations have already expanded. A clean breakout through the 3.0–3.2 USD band on volume and without immediate failure would strengthen the bullish technical case and open up room towards prior congestion zones well above current levels. Conversely, a sharp rejection around this band – especially if coupled with disappointing tone on the call or slower-than-hoped Elfabrio trends – would fit a more classical “buy the rumour, sell the news” pattern and re-expose the mid-range.

None of this replaces fundamental work, but it frames the setup: whoever trades PLX into March is not operating in a vacuum. The tape is already signalling that a non-trivial portion of the good news is in the price.

5. Risk map – what can go wrong from here

5.1. Concentration on a handful of products and partners

Protalix remains heavily exposed to a small number of commercial relationships. The bulk of product revenues hinges on Elfabrio and Elelyso, depending on a limited set of counterparties and on the ability to maintain competitive positioning against other ERTs. Any disruption on the partner side – strategy shifts, pricing pressures, or safety signals impacting the class – would have an outsized impact.

5.2. Regulatory and reimbursement dynamics

The CHMP’s positive opinion on E4W is a strong step, but it is not risk-free until the Commission’s decision is formally in the label and payers have adjusted. Reimbursement and access patterns can differ meaningfully between EU markets; some may take time to fully embrace the less frequent dosing regimen, or they may tie it to specific patient subsets. In parallel, the U.S. has not yet seen an E4W decision, and any divergences between EU and U.S. labelling or payer behaviour would complicate the picture.

5.3. Pipeline execution and dilution

On the pipeline side, the risk is mostly about time and capital. If PRX-115 progresses more slowly than expected, or if early trial signals are ambiguous, the market could start treating it as an option with limited probability of success rather than as a core value driver. Meanwhile, even with profitable years on paper, Protalix may still choose to raise equity at some point to support clinical work and buffer the balance sheet, especially if non-dilutive milestone timing slips.

5.4. Small-cap liquidity and volatility

As always with small-cap biotech names, liquidity and volatility are part of the package. Bid/ask spreads can widen on bad tape days, short-term moves can overshoot both on the upside and on the downside, and investor positioning can flip quickly around events. None of that makes PLX “good” or “bad” as an investment case; it simply reinforces the point that position sizing, time horizon and risk tolerance matter as much as the underlying story.

6. Sentiment & positioning – how the crowd is treating PLX

Retail and semi-professional sentiment around PLX has improved along with the price. Discussions on social platforms and message boards remain those of a niche community rather than a crowded momentum trade, but the tone has shifted from “will the company survive?” to “how far can Elfabrio and gout take it?”. That is a healthier backdrop, yet also one that leaves less room for upside surprises if things merely go “OK”.

Note: all sentiment observations above are based on public comments and posts from non-professional market participants. They are included purely as an illustration of crowd behaviour and should not be interpreted as advice, consensus or validation.

7. How this report connects to our previous PLX coverage

This follow-up is meant to sit on top of our earlier PLX write-ups rather than replace them. The prior pieces provide more background on Fabry disease, on the competitive landscape in enzyme replacement therapy and on the mechanics of the ProCellEx platform. Here, the focus is narrower: the March 2026 catalyst cluster and the fact that the stock is now sitting at a very different technical and fundamental starting point.